Picture [LSUS] – The Business Web Portal 600x60px
Document › Details

Immunicum AB. (12/29/17). "Press Release: Immunicum AB (publ) Announces the Outcome of the Rights Issue [Not for US, AU, CA, et al.]".

Organisations Organisation Immunicum AB (publ) (Nasdaq Stockholm: IMMU.ST)
  Organisation 2 Nasdaq Stockholm
  Group Nasdaq OMX (Group)
Products Product ilixadencel
  Product 2 investment banking
Index term Index term Immunicum–SEVERAL: investment, 201711–201712 capital increase SEK200m net SEK168m with 25m new shares at SEK8/share
Persons Person de Sousa, Carlos (Immunicum 201610– CEO before Zealand Pharma + Nycomed/Takeda + Pfizer + Novartis + BBB Therapeutics)
  Person 2 Schweitzer, Gretchen (Trophic Comunications 201801 before MacDougall European Office)

Record changed: 2018-10-20


Picture [LSA] – The Business Web Portal 650x89px

More documents for Immunicum AB (publ) (Nasdaq Stockholm: IMMU.ST)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px

» top